Literature DB >> 27656419

Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map?

Nathan A Berger1.   

Abstract

Entities:  

Year:  2016        PMID: 27656419      PMCID: PMC5028114          DOI: 10.21037/tcr.2016.08.07

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN: 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  24 in total

Review 1.  Novel therapeutic targets for pancreatic cancer.

Authors:  Shing-Chun Tang; Yang-Chao Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance.

Authors:  Bridget Keenan; Elizabeth M Jaffee
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

Review 3.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Authors:  Mustafa Suker; Berend R Beumer; Eran Sadot; Lysiane Marthey; Jason E Faris; Eric A Mellon; Bassel F El-Rayes; Andrea Wang-Gillam; Jill Lacy; Peter J Hosein; Sing Yu Moorcraft; Thierry Conroy; Florian Hohla; Peter Allen; Julien Taieb; Theodore S Hong; Ravi Shridhar; Ian Chau; Casper H van Eijck; Bas Groot Koerkamp
Journal:  Lancet Oncol       Date:  2016-05-06       Impact factor: 41.316

Review 4.  Smarter drugs emerging in pancreatic cancer therapy.

Authors:  A Kleger; L Perkhofer; T Seufferlein
Journal:  Ann Oncol       Date:  2014-03-14       Impact factor: 32.976

5.  Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Authors:  Pawel K Mazur; Alexander Herner; Stephano S Mello; Matthias Wirth; Simone Hausmann; Francisco J Sánchez-Rivera; Shane M Lofgren; Timo Kuschma; Stephan A Hahn; Deepak Vangala; Marija Trajkovic-Arsic; Aayush Gupta; Irina Heid; Peter B Noël; Rickmer Braren; Mert Erkan; Jörg Kleeff; Bence Sipos; Leanne C Sayles; Mathias Heikenwalder; Elisabeth Heßmann; Volker Ellenrieder; Irene Esposito; Tyler Jacks; James E Bradner; Purvesh Khatri; E Alejandro Sweet-Cordero; Laura D Attardi; Roland M Schmid; Guenter Schneider; Julien Sage; Jens T Siveke
Journal:  Nat Med       Date:  2015-09-21       Impact factor: 53.440

Review 6.  Cancer epigenetics drug discovery and development: the challenge of hitting the mark.

Authors:  Robert M Campbell; Peter J Tummino
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 7.  Pancreatic cancer.

Authors:  Jorg Kleeff; Murray Korc; Minoti Apte; Carlo La Vecchia; Colin D Johnson; Andrew V Biankin; Rachel E Neale; Margaret Tempero; David A Tuveson; Ralph H Hruban; John P Neoptolemos
Journal:  Nat Rev Dis Primers       Date:  2016-04-21       Impact factor: 52.329

8.  Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells.

Authors:  Raewyn Broady; Jie Yu; Vickie Chow; Adisak Tantiworawit; Christine Kang; Kyra Berg; Magdalena Martinka; Mehran Ghoreishi; Jan Dutz; Megan K Levings
Journal:  Blood       Date:  2010-09-23       Impact factor: 22.113

Review 9.  Obesity, energy balance, and cancer: new opportunities for prevention.

Authors:  Stephen D Hursting; John Digiovanni; Andrew J Dannenberg; Maria Azrad; Derek Leroith; Wendy Demark-Wahnefried; Madhuri Kakarala; Angela Brodie; Nathan A Berger
Journal:  Cancer Prev Res (Phila)       Date:  2012-10-03

Review 10.  Potential of epigenetic therapies in the management of solid tumors.

Authors:  Victor Valdespino; Patricia M Valdespino
Journal:  Cancer Manag Res       Date:  2015-07-31       Impact factor: 3.989

View more
  1 in total

1.  CD90 positive cells exhibit aggressive radioresistance in esophageal squamous cell carcinoma.

Authors:  Yuandong Wang; Chi Zhang; Hongcheng Zhu; Junwei Tang; Shu Zhang; Jinhua Luo; Xinchen Sun
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.